Barcelona, Spain-based Inbrain Neuroelectronics, a company dedicated to the development of graphene-based neural technologies for BCI therapeutic interfaces (BCI-Tx), has signed a collaboration agreement with well-known US healthcare services provider Mayo Clinic, headquartered in Rochester, Minnesota

The goal is to accelerate the development and commercialisation of Inbrain’s precision BCI-Tx technology for patients with neurological disorders by conducting a practical evaluation in clinical trials.

The technology combines precise BCI decoding with micron-level modulation to deliver adaptive and personalised treatments for conditions such as Parkinson’s disease, epilepsy and stroke rehabilitation. By providing continuous, real-time monitoring and autonomous therapeutic adjustments, the AI-powered platform is said to maximise outcomes and minimise side effects.

“Our goal is to maximise the unique capabilities of graphene and artificial intelligence to generate true value for both patients and medical teams,” said Carolina Aguilar, CEO and co-founder of Inbrain Neuroelectronics. “With Mayo Clinic’s clinical expertise alongside other leading centres in the USA and Europe, we are seeking to validate our platform in real-world settings, accelerate clinical evidence and responsibly advance patient-centered BCI therapies.”

Inbrain has also formed a US subsidiary and an initial Boston office will serve as the hub for the US clinical trials.

Inbrain has raised $124 million in funding to date from an international consortium of medical technology and deep tech investors.

Mayo Clinic also has a financial interest in the technology and will use any proceeds it receives from it to fund its non-profit mission of patient care, education and research.

www.inbrain-neuroelectronics.com